A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs PRO 1286 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genmab
- 27 Nov 2024 Status changed from not yet recruiting to recruiting.
- 19 Nov 2024 New trial record